GlaxoSmithKline Pharmaceuticals net profit rises 9.45% to Rs 165 cr in Q3

GlaxoSmithKline Pharmaceuticals Ltd reported a 9.45% rise in consolidated net profit at Rs 164.56 crore in the third quarter ended December 31, 2022

GSK, GlaxoSmithKline
Press Trust of India New Delhi
1 min read Last Updated : Feb 07 2023 | 8:36 PM IST

GlaxoSmithKline Pharmaceuticals Ltd on Tuesday reported a 9.45 per cent rise in consolidated net profit at Rs 164.56 crore in the third quarter ended December 31, 2022.

The company had posted a consolidated net profit of Rs 150.35 crore in the same quarter last fiscal, GlaxoSmithKline Pharmaceuticals (GSK Pharma) said in a regulatory filing.

Consolidated revenue from operations during the quarter under review stood at Rs 802.3 crore as against Rs 815.92 crore in the year-ago period, it added.

Total expenses were lower at Rs 590.1 crore compared to Rs 636.56 crore in the corresponding quarter last fiscal.

"General medicines portfolio grew by 10 per cent led by anti-infectives and dermatology therapies...Vaccine sales were down for the quarter in a declining self-pay vaccines market. However, we continue to gain market share for key vaccine brands," GSK Pharma Managing Director Bhushan Akshikar said.

During the quarter, he said, the National List of Essential Medicines (NLEM), 2022 was announced.

"The list includes 16 GSK brands, of which revised prices have been notified for eight brands. We will continue to drive various initiatives to mitigate the impact of the same," Akshikar said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :GlaxoSmithKline PharmaceuticalsQ3 resultsMarkets

First Published: Feb 07 2023 | 8:36 PM IST

Next Story